<DOC>
	<DOCNO>NCT02601209</DOCNO>
	<brief_summary>This partially randomized phase I/II trial study side effect best dose sapanisertib see well work compare pazopanib hydrochloride treat patient sarcoma large remove ( locally advance ) spread area body ( metastatic ) . Sapanisertib pazopanib hydrochloride may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Sapanisertib Pazopanib Hydrochloride Treating Patients With Locally Advanced Metastatic Sarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety maximum tolerable dose sapanisertib ( MLN0128 [ TAK-228 ] ) within patient population . ( Phase I ) II . To determine difference progression-free survival ( PFS ) patient sarcoma receive MLN0128 ( TAK-228 ) compare pazopanib ( pazopanib hydrochloride ) . ( Phase II ) SECONDARY OBJECTIVES : I . To evaluate adverse event . ( Phase I/II ) II . To evaluate overall response rate ( ORR ) , clinical benefit rate ( CBR ) , duration response ( DOR ) . ( Phase I/II ) III . To evaluate time progression ( TTP ) overall survival ( OS ) . ( Phase I/II ) TERTIARY OBJECTIVES : I . To evaluate PFS secondary endpoint within patient cross MLN0128 ( TAK-228 ) , upon disease progression treatment pazopanib . ( Phase II ) II . To evaluate 4 month CBR observe within patient treat MLN0128 ( TAK-228 ) group histologically define cohort . ( Phase II ) OUTLINE : This phase I , dose-escalation study , follow randomized phase II study . PHASE I : Patients receive sapanisertib orally ( PO ) day 1 , 8 , 15 , 22 absence disease progression unacceptable toxicity . PHASE II : Patients randomize 1 2 treatment arm . ARM I : Patients receive sapanisertib Phase I . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM II : Patients receive pazopanib hydrochloride PO daily ( QD ) day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients experience disease progression may crossover Arm I . After completion study treatment , patient follow 4 week every 6 month 2 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neurofibrosarcoma</mesh_term>
	<mesh_term>Histiocytoma , Malignant Fibrous</mesh_term>
	<criteria>Patients must slide available submission central pathology review ; review mandatory prior registration confirm eligibility proper cohort assignment HISTOLOGIC COHORT 1 : Undifferentiated pleomorphic sarcoma ( include : malignant fibrous histiocytoma , myxofibrosarcoma , high grade sarcoma otherwise specify [ NOS ] ) HISTOLOGIC COHORT 2 : Leiomyosarcoma ( either uterine extrauterine ) HISTOLOGIC COHORT 3 : Other ( either malignant peripheral nerve sheath tumor synovial sarcoma ) ; phase II portion study , enrollment limit maximum 25 patient cohort Note phase I limit histologic subtypes list ; since patient enrol onto dose cohort phase I , enroll onto specific histologic cohort , although histologic subtype inform collect patient enrollment Histologic documentation : Eligible patient must histopathologically confirm sarcoma one subtypes list , central review Locally advance metastatic disease ; locally advance disease define disease amenable local therapy surgery and/or radiation Measurable disease Progression least one prior systemic chemotherapy advance , unresectable metastatic disease ; prior adjuvant neoadjuvant therapy include prior systemic chemotherapy unless treatment occur within 6 month prior study enrollment There limit number prior line treatment patient receive No treatment biological therapy , immunotherapy , chemotherapy , investigational agent malignancy , radiation = &lt; 28 day study registration ; treatment nitrosourea mitomycin = &lt; 42 day study registration No treatment radiation therapy = &lt; 28 day study registration Patients resolution toxic effect prior therapy ( except alopecia ) National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , version 4.0 , grade 1 less Prior treatment pazopanib phosphoinositide 3kinase ( PI3K ) , mTOR , protein kinase B ( AKT ) , dual PI3K/mTOR complex ( CREB regulate transcription coactivator [ TORC ] 1/TORC2 ) inhibitor prohibit Not pregnant nursing ; woman childbearing potential , negative pregnancy test do = &lt; 7 day prior registration require Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 Patient history : patient follow NOT eligible : Central nervous system ( CNS ) : Symptomatic , untreated , uncontrolled brain metastasis present Heme : Active bleeding bleed diathesis Gastrointestinal ( GI ) : Abdominal fistula , GI perforation , intraabdominal abscess within 28 day prior registration Acute GI bleed within 28 day registration Diabetes mellitus : Patients diabetes mellitus inadequate control , base either glycosylated hemoglobin ( Hgb A1c ) &lt; 7.0 fast blood glucose 126 mg/dL Cardiac vascular disorder : History congenital long QT syndrome torsades de pointes Any arrhythmia currently ratecontrolled ( rate 60 100 ) Prolongation correct QT interval via Fridericia 's formula ( QTcF ) &gt; 480 msec Ongoing unstable angina Symptomatic peripheral vascular disease Arterial thrombosis within 28 day registration include transient ischemic attack ( TIA ) , cerebrovascular accident ( CVA ) , myocardial infarction ( MI ) Patients deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) must stable dose anticoagulation 14 day prior registration Uncontrolled hypertension , define blood pressure ( BP ) &gt; 140/90 Multi gate acquisition scan ( MUGA ) ejection fraction ( EF ) , 50 % echocardiogram ( echo ) low EF Class III IV congestive heart failure ( CHF ) within 28 day registration Chronic concomitant treatment proton pump inhibitor must discontinue drug 7 day prior registration study Chronic concomitant treatment strong inhibitor cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inhibitor must discontinue drug 14 day prior registration study Chronic concomitant treatment strong CYP3A4 inducer allow ; patient must discontinue drug 14 day prior start study treatment Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 Creatinine = &lt; 1.5 x upper limit normal ( ULN ) Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) ; unless patient Gilbert disease Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) = &lt; 3 x upper limit normal ( ULN ) ; liver metastasis , = &lt; 5 x upper limit normal ( ULN ) Urine protein creatinine ( UPC ) = &lt; 1 ; UPC &gt; = 1 , 24hour urine protein must assess ; eligible patient must 24hour urine protein value &lt; 1 g/L Thyroid stimulate hormone ( TSH ) within normal limit ( WNL ) ; supplementation acceptable achieve TSH WNL ; patient abnormal TSH however Free T4 normal patient clinically euthyroid , patient eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>